Wall Street analysts expect that Epizyme Inc (NASDAQ:EPZM) will post sales of $1.13 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Epizyme’s earnings, with the highest sales estimate coming in at $1.25 million and the lowest estimate coming in at $1.00 million. The company is expected to issue its next earnings report on Tuesday, May 14th.

According to Zacks, analysts expect that Epizyme will report full-year sales of $7.77 million for the current fiscal year, with estimates ranging from $5.00 million to $15.00 million. For the next year, analysts anticipate that the business will post sales of $35.90 million, with estimates ranging from $5.18 million to $70.90 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Epizyme.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Tuesday, February 26th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.17.

A number of analysts have issued reports on the stock. BidaskClub downgraded shares of Epizyme from a “strong-buy” rating to a “buy” rating in a report on Friday, February 22nd. Oppenheimer dropped their price target on shares of Epizyme from $27.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 27th. Zacks Investment Research raised shares of Epizyme from a “hold” rating to a “buy” rating and set a $9.00 price target on the stock in a research report on Monday, January 7th. ValuEngine raised shares of Epizyme from a “sell” rating to a “hold” rating in a research report on Saturday, December 15th. Finally, Roth Capital reissued a “buy” rating on shares of Epizyme in a research report on Wednesday, February 27th. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Epizyme currently has an average rating of “Buy” and a consensus price target of $18.40.

Several institutional investors have recently made changes to their positions in EPZM. Norges Bank acquired a new position in shares of Epizyme in the 4th quarter valued at $6,965,000. Opaleye Management Inc. increased its holdings in Epizyme by 462.5% during the 4th quarter. Opaleye Management Inc. now owns 1,125,000 shares of the biopharmaceutical company’s stock worth $6,930,000 after purchasing an additional 925,000 shares during the period. BlackRock Inc. increased its holdings in Epizyme by 19.0% during the 4th quarter. BlackRock Inc. now owns 5,193,287 shares of the biopharmaceutical company’s stock worth $31,990,000 after purchasing an additional 830,815 shares during the period. Millennium Management LLC increased its holdings in Epizyme by 521.5% during the 4th quarter. Millennium Management LLC now owns 818,800 shares of the biopharmaceutical company’s stock worth $5,044,000 after purchasing an additional 687,047 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in Epizyme by 259.8% during the 3rd quarter. Point72 Asset Management L.P. now owns 669,300 shares of the biopharmaceutical company’s stock worth $7,095,000 after purchasing an additional 483,300 shares during the period. 72.63% of the stock is currently owned by institutional investors and hedge funds.

EPZM traded up $0.24 on Monday, reaching $12.21. The company had a trading volume of 12,974 shares, compared to its average volume of 999,242. The firm has a market cap of $1.09 billion, a P/E ratio of -7.09 and a beta of 3.15. Epizyme has a fifty-two week low of $5.14 and a fifty-two week high of $18.70.

Epizyme Company Profile

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Recommended Story: Why do corrections happen?

Get a free copy of the Zacks research report on Epizyme (EPZM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.